Jeongwon Choi

Supplementary Figures from Activation of NKT Cells in an Anti-PD-1–Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells

Eun‐Ah Bae, Hyungseok Seo, Byung Seok Kim, Jeongwon Choi et autres

Supplementary Figures

Data from Activation of NKT Cells in an Anti-PD-1–Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells

Eun‐Ah Bae, Hyungseok Seo, Byung Seok Kim, Jeongwon Choi et autres

Abstract PD-1–based cancer immunotherapy is a successful example of immune checkpoint blockade that provides long-term durable therapeutic effects in patients with cancer across a wide spectrum of cancer types. Accumulating evidence suggests that anti-PD-1 therapy enhances antitumor immunity by reversing the function …

NKT cell ligand-induced cytokines enhance antitumor effects with PD-1 blockade by reinvigorating exhausted CD8 T cells.

Eun-Ah Bae, Hyungseok Seo, Jeongwon Choi, Jeongmi Lee et autres

Abstract Various immune checkpoint blockades have shown great promise for cancer patients. Anti-PD-1 therapies are known to reinvigorate exhausted immune cells, which progressively have lost effector function after chronic exposure to antigen. Although anti-PD-1 blockades were tested in various clinical trials on …

kr, th (code pays fourni par la source)

Analysis of immunogenicity of different sizes of HER2/neu antigen

Insu Jeon, Hyungseok Seo, Myung Hwan Park, Kwang-Soo Shin et autres

Abstract One of the most important factors of cancer immunotherapeutic vaccine is to induce tumor antigen specific T cell response. Prior to considering how to induce T cell response efficiently, researchers should select tumor antigen with careful consideration because some tumor antigen …

kr, th (code pays fourni par la source)